Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab.

Although the differences among these groups did not reach statistical significance, it was nevertheless interesting that the highest increases in both double-positive ( Fig. 7A and B ) and triple-positive ( Fig. 7C ) responding CD4 + T cells were observed in the relatlimab plus nivolumab combination group compared with the groups receiving either drug alone.

also in 111,027 other papers